Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy

Abstract

No AccessJournal of UrologyAdult Urology1 Jul 2009Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsyis accompanied byPhase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer Michael J. Donovan, Faisal M. Khan, Gerardo Fernandez, Ricardo Mesa-Tejada, Marina Sapir, Valentina Bayer Zubek, Douglas Powell, Stephen Fogarasi, Yevgen Vengrenyuk, Mikhail Teverovskiy, Mark R. Segal, R. Jeffrey Karnes, Thomas A. Gaffey, Christer Busch, Michael Haggman, Peter Hlavcak, Stephen J. Freedland, Robin T. Vollmer, Peter Albertsen, Jose Costa, and Carlos Cordon-Cardo Michael J. DonovanMichael J. Donovan Aureon Laboratories, Inc., New York, New York , Faisal M. KhanFaisal M. Khan Aureon Laboratories, Inc., New York, New York , Gerardo FernandezGerardo Fernandez Aureon Laboratories, Inc., New York, New York , Ricardo Mesa-TejadaRicardo Mesa-Tejada Aureon Laboratories, Inc., New York, New York Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York , Marina SapirMarina Sapir Aureon Laboratories, Inc., New York, New York , Valentina Bayer ZubekValentina Bayer Zubek Aureon Laboratories, Inc., New York, New York , Douglas PowellDouglas Powell Aureon Laboratories, Inc., New York, New York , Stephen FogarasiStephen Fogarasi Aureon Laboratories, Inc., New York, New York , Yevgen VengrenyukYevgen Vengrenyuk Aureon Laboratories, Inc., New York, New York , Mikhail TeverovskiyMikhail Teverovskiy Aureon Laboratories, Inc., New York, New York , Mark R. SegalMark R. Segal Center for Bioinformatics and Molecular Biostatistics, University of California-San Francisco, San Francisco, California , R. Jeffrey KarnesR. Jeffrey Karnes Mayo Clinic, Rochester, Minnesota , Thomas A. GaffeyThomas A. Gaffey Mayo Clinic, Rochester, Minnesota , Christer BuschChrister Busch University Hospital at Uppsala, Uppsala, Sweden , Michael HaggmanMichael Haggman University Hospital at Uppsala, Uppsala, Sweden , Peter HlavcakPeter Hlavcak University Hospital at Uppsala, Uppsala, Sweden , Stephen J. FreedlandStephen J. Freedland Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina , Robin T. VollmerRobin T. Vollmer Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina , Peter AlbertsenPeter Albertsen University of Connecticut Health Science Center, Farmington, Connecticut , Jose CostaJose Costa Aureon Laboratories, Inc., New York, New York Yale University School of Medicine, New Haven, Connecticut , and Carlos Cordon-CardoCarlos Cordon-Cardo Aureon Laboratories, Inc., New York, New York Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York View All Author Informationhttps://doi.org/10.1016/j.juro.2009.02.135AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To our knowledge in patients with prostate cancer there are no available tests except clinical variables to determine the likelihood of disease progression. We developed a patient specific, biology driven tool to predict outcome at diagnosis. We also investigated whether biopsy androgen receptor levels predict a durable response to therapy after secondary treatment. Materials and Methods: We evaluated paraffin embedded prostate needle biopsy tissue from 1,027 patients with cT1c-T3 prostate cancer treated with surgery and followed a median of 8 years. Machine learning was done to integrate clinical data with biopsy quantitative biometric features. Multivariate models were constructed to predict disease progression with the C index to estimate performance. Results: In a training set of 686 patients (total of 87 progression events) 3 clinical and 3 biopsy tissue characteristics were identified to predict clinical progression within 8 years after prostatectomy with 78% sensitivity, 69% specificity, a C index of 0.74 and a HR of 5.12. Validation in an independent cohort of 341 patients (total of 44 progression events) yielded 76% sensitivity, 64% specificity, a C index of 0.73 and a HR of 3.47. Increased androgen receptor in tumor cells in the biopsy highly significantly predicted resistance to therapy, ie androgen ablation with or without salvage radiotherapy, and clinical failure (p <0.0001). Conclusions: Morphometry reliably classifies Gleason pattern 3 tumors. When combined with biomarker data, it adds to the hematoxylin and eosin analysis, and prostate specific antigen values currently used to assess outcome at diagnosis. Biopsy androgen receptor levels predict the likelihood of a response to therapy after recurrence and may guide future treatment decisions. References 1 : Cancer statistics, 2008. CA Cancer J Clin2008; 58: 71. Google Scholar 2 : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med2002; 347: 781. Google Scholar 3 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005; 352: 1977. Google Scholar 4 : Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol2006; 7: 355. Google Scholar 5 : Active surveillance for early-stage prostate cancer: review of the current literature. Cancer2008; 112: 1650. Google Scholar 6 : 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA2005; 293: 2095. Google Scholar 7 : Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics2008; 64: 10. Google Scholar 8 : Case 15-2008: a 55 year-old-man with an elevated prostate-specific antigen level and early-stage prostate cancer. N Engl J Med2008; 358: 2161. Google Scholar 9 : Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology2007; 69: 1095. Google Scholar 10 : Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006; 98: 715. Google Scholar 11 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar 12 : Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest2007; 117: 1876. Google Scholar 13 : A systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol2008; 26: 3923. Google Scholar 14 : Syntactic structure analysis in invasive breast cancer: analysis of reproducibility, biologic background, and prognostic value. Hum Pathol1992; 23: 876. Google Scholar 15 : A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst1998; 90: 766. Crossref, Medline, Google Scholar 16 : Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urol Oncol Semin Orig Invest2008; 26: 408. Google Scholar 17 : Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol2002; 20: 3972. Google Scholar 18 : Simpson's paradox, Lord's paradox, and Suppression Effects are the same phenomenon—the reversal paradox. Emerg Themes Epidemiol2008; 5: 2. Google Scholar 19 : Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology2006; 67: 115. Google Scholar 20 : Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol2004; 11: 2157. Google Scholar 21 : Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol2008; 53: 767. Google Scholar 22 : Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol1998; 29: 949. Google Scholar 23 : Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst2000; 92: 1941. Google Scholar 24 : Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92–02. J Clin Oncol2004; 22: 2133. Google Scholar 25 : Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res2006; 26: 4873. Google Scholar 26 : Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int2007; 100: 685. Google Scholar 27 : Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets2007; 7: 591. Google Scholar 28 : Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer2008; 98: 1094. Google Scholar 29 : Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?. Acta Oncol2005; 44: 362. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byTaneja S (2020) Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-Based, Diagnostic StudyJournal of Urology, VOL. 204, NO. 3, (620-621), Online publication date: 1-Sep-2020.Related articlesJournal of Urology18 May 2009Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer Volume 182Issue 1July 2009Page: 125-132 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsreceptorsbiological markersprostatebiopsyandrogenprostatic neoplasmsAcknowledgmentsDrs. Vijay Aggarwal, Robert Shovlin, Jason Alter and Charles DiComo contributed to the manuscript. Dr. William M. Pottenger, Rutgers University performed the randomized training/test split of the data. Mark Clayton, and Drs. Stefan Hamann, Paola Capodieci and Ali Tabesh, Aureon Laboratories; Dr. Angelique W. Levi, Aureon Laboratories and Yale University School of Medicine; Dr. Mona Norberg, University Hospital at Uppsala, Dr. Jayakrishnan Jayachandran and Leah Gerber, Durham Veterans Affairs and Duke University Medical Center; and Judith Fine, University of Connecticut Health Science Center provided clinical database and technical support. The cohort was randomized and split at Rutgers University.Metrics Author Information Michael J. Donovan Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Faisal M. Khan Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Gerardo Fernandez Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Ricardo Mesa-Tejada Aureon Laboratories, Inc., New York, New York Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Marina Sapir Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Valentina Bayer Zubek Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Douglas Powell Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Stephen Fogarasi Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Yevgen Vengrenyuk Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Mikhail Teverovskiy Aureon Laboratories, Inc., New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Mark R. Segal Center for Bioinformatics and Molecular Biostatistics, University of California-San Francisco, San Francisco, California Financial interest and/or other relationship with Aureon Laboratories. More articles by this author R. Jeffrey Karnes Mayo Clinic, Rochester, Minnesota More articles by this author Thomas A. Gaffey Mayo Clinic, Rochester, Minnesota More articles by this author Christer Busch University Hospital at Uppsala, Uppsala, Sweden More articles by this author Michael Haggman University Hospital at Uppsala, Uppsala, Sweden More articles by this author Peter Hlavcak University Hospital at Uppsala, Uppsala, Sweden More articles by this author Stephen J. Freedland Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Robin T. Vollmer Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina More articles by this author Peter Albertsen University of Connecticut Health Science Center, Farmington, Connecticut Financial interest and/or other relationship with Sanofi, Bristol Meyers, Galaxo and Blue Cross Blue Shield. More articles by this author Jose Costa Aureon Laboratories, Inc., New York, New York Yale University School of Medicine, New Haven, Connecticut Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Carlos Cordon-Cardo Aureon Laboratories, Inc., New York, New York Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York Financial interest and/or other relationship with Aureon Laboratories. More articles by this author Expand All Advertisement PDF downloadLoading ...